全文获取类型
收费全文 | 208734篇 |
免费 | 9387篇 |
国内免费 | 408篇 |
学科分类
医药卫生 | 218529篇 |
出版年
2023年 | 1011篇 |
2021年 | 2251篇 |
2020年 | 1773篇 |
2019年 | 2241篇 |
2018年 | 3851篇 |
2017年 | 3154篇 |
2016年 | 4244篇 |
2015年 | 4624篇 |
2014年 | 5124篇 |
2013年 | 7111篇 |
2012年 | 10749篇 |
2011年 | 10267篇 |
2010年 | 5810篇 |
2009年 | 4919篇 |
2008年 | 9736篇 |
2007年 | 10622篇 |
2006年 | 10469篇 |
2005年 | 10874篇 |
2004年 | 10198篇 |
2003年 | 10004篇 |
2002年 | 9673篇 |
2001年 | 7035篇 |
2000年 | 7086篇 |
1999年 | 6157篇 |
1998年 | 2010篇 |
1997年 | 1635篇 |
1996年 | 1197篇 |
1995年 | 1039篇 |
1994年 | 955篇 |
1993年 | 901篇 |
1992年 | 2852篇 |
1991年 | 2778篇 |
1990年 | 2733篇 |
1989年 | 2507篇 |
1988年 | 2218篇 |
1987年 | 2234篇 |
1986年 | 2078篇 |
1985年 | 2008篇 |
1984年 | 1537篇 |
1983年 | 1220篇 |
1979年 | 1615篇 |
1978年 | 1177篇 |
1977年 | 992篇 |
1975年 | 1222篇 |
1974年 | 1291篇 |
1973年 | 1177篇 |
1972年 | 1171篇 |
1971年 | 1118篇 |
1970年 | 995篇 |
1969年 | 929篇 |
排序方式: 共有10000条查询结果,搜索用时 390 毫秒
1.
Georg Prokop Benedikt Wiestler Daniel Hieber Fynn Withake Karoline Mayer Jens Gempt Claire Delbridge Friederike Schmidt-Graf Nicole Pfarr Bruno Märkl Jürgen Schlegel Friederike Liesche-Starnecker 《International journal of cancer. Journal international du cancer》2023,153(9):1658-1670
Intratumor heterogeneity is a main cause of the dismal prognosis of glioblastoma (GBM). Yet, there remains a lack of a uniform assessment of the degree of heterogeneity. With a multiscale approach, we addressed the hypothesis that intratumor heterogeneity exists on different levels comprising traditional regional analyses, but also innovative methods including computer-assisted analysis of tumor morphology combined with epigenomic data. With this aim, 157 biopsies of 37 patients with therapy-naive IDH-wildtype GBM were analyzed regarding the intratumor variance of protein expression of glial marker GFAP, microglia marker Iba1 and proliferation marker Mib1. Hematoxylin and eosin stained slides were evaluated for tumor vascularization. For the estimation of pixel intensity and nuclear profiling, automated analysis was used. Additionally, DNA methylation profiling was conducted separately for the single biopsies. Scoring systems were established to integrate several parameters into one score for the four examined modalities of heterogeneity (regional, cellular, pixel-level and epigenomic). As a result, we could show that heterogeneity was detected in all four modalities. Furthermore, for the regional, cellular and epigenomic level, we confirmed the results of earlier studies stating that a higher degree of heterogeneity is associated with poorer overall survival. To integrate all modalities into one score, we designed a predictor of longer survival, which showed a highly significant separation regarding the OS. In conclusion, multiscale intratumor heterogeneity exists in glioblastoma and its degree has an impact on overall survival. In future studies, the implementation of a broadly feasible heterogeneity index should be considered. 相似文献
2.
Mette Nissen Tiina‐Mari Ikheimo Jukka Huttunen Ville Leinonen Henna‐Kaisa Jyrkknen Mikael von und zu Fraunberg 《Neuromodulation》2021,24(1):102-111
ObjectiveSpinal cord stimulation (SCS) is an effective treatment in failed back surgery syndrome (FBSS). We studied the effect of preimplantation opioid use on SCS outcome and the effect of SCS on opioid use during a two-year follow-up period.Materials and methodsThe study cohort included 211 consecutive FBSS patients who underwent an SCS trial from January 1997 to March 2014. Participants were divided into groups, which were as follows: 1) SCS trial only (n = 47), 2) successful SCS (implanted and in use throughout the two-year follow-up period, n = 131), and 3) unsuccessful SCS (implanted but later explanted or revised due to inadequate pain relief, n = 29). Patients who underwent explantation for other reasons (n = 4) were excluded. Opioid purchase data from January 1995 to March 2016 were retrieved from national registries.ResultsHigher preimplantation opioid doses associated with unsuccessful SCS (ROC: AUC = 0.66, p = 0.009), with 35 morphine milligram equivalents (MME)/day as the optimal cutoff value. All opioids were discontinued in 23% of patients with successful SCS, but in none of the patients with unsuccessful SCS (p = 0.004). Strong opioids were discontinued in 39% of patients with successful SCS, but in none of the patients with unsuccessful SCS (p = 0.04). Mean opioid dose escalated from 18 ± 4 MME/day to 36 ± 6 MME/day with successful SCS and from 22 ± 8 MME/day to 82 ± 21 MME/day with unsuccessful SCS (p < 0.001).ConclusionsHigher preimplantation opioid doses were associated with SCS failure, suggesting the need for opioid tapering before implantation. With continuous SCS therapy and no explantation or revision due to inadequate pain relief, 39% of FBSS patients discontinued strong opioids, and 23% discontinued all opioids. This indicates that SCS should be considered before detrimental dose escalation. 相似文献
3.
Hommes Franziska Mohsenpour Amir Kropff Dana Pilgram Lisa Matusall Svenja von Philipsborn Peter Sell Kerstin 《Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz》2022,65(1):96-106
Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz - Akteure der öffentlichen Gesundheit (Public Health) tragen wesentlich zu Gesundheitsschutz, -förderung und... 相似文献
4.
5.
6.
Esin Benli Küçük Ercan Kaydok Kürsad Ramazan Zor Gamze Yıldırım Biçer 《Topics in stroke rehabilitation》2020,27(8):630-635
ABSTRACT Objective: Dry eye is reported to be associated with several neurological diseases. The aim of this study is to evaluate the patients with hemiplegia after stroke for dry eye and compare their results with a control group. Materials and methods: Forty-five patients with hemiplegia and 45 individuals as the control group were included in the study. Tear function tests (Schirmer and tear breakup time) and a dry eye questionnaire for dry eye symptoms (ocular surface disease index) were performed and the results of the two groups were compared. Results: Schirmer test results were significantly lower in the post-stroke hemiplegia group compared to the control group (11.3 ± 8.2 mm and 20.6 ± 11.6 mm, respectively, p < .001). Tear breakup time results were significantly lower in the post-stroke hemiplegia group compared to the control group (7.9 ± 3.1 s and 12.1 ± 4.3 s, respectively, p < .001). Ocular surface disease index scores were not significantly different between hemiplegia and control groups (21.6 ± 20.0 and 19.8 ± 13.9, respectively, p = .635). Schirmer scores lower than 10 mm (60% and 30%, p < .001) and tear breakup time results lower than 10 s (65.6% and 28.9%, p < .001) were also higher in the hemiplegia group compared to control group. Conclusion: We found lower Schirmer test and tear breakup time results and similar OSDI scores in hemiplegia patients compared to controls. Hemiplegia patients may have dry eye without typical symptoms. This should be taken into consideration in the follow-up and rehabilitation of post-stroke hemiplegia patients. 相似文献
7.
8.
9.
10.
Key Jana Maletzko Antonia Kohli Aneesha Gispert Suzana Torres-Odio Sylvia Wittig Ilka Heidler Juliana Bárcena Clea López-Otín Carlos Lei Yuanjiu West A. Phillip Münch Christian Auburger Georg 《Neurogenetics》2020,21(3):187-203
neurogenetics - Human RNF213, which encodes the protein mysterin, is a known susceptibility gene for moyamoya disease (MMD), a cerebrovascular condition with occlusive lesions and compensatory... 相似文献